Calcium Pyrophosphate Deposition (CPPD) Disease

Launched by LILLE CATHOLIC UNIVERSITY · May 26, 2025

Keywords

ClinConnect Summary

This clinical trial is studying Calcium Pyrophosphate Deposition Disease (CPPD), a type of arthritis that can cause joint pain and swelling. Researchers want to understand the differences between people with chronic CPPD, which lasts a long time, and those with acute CPPD, which comes on suddenly. They will look at the genetic and metabolic profiles of patients to see if these factors explain why some treatments work better for certain people. The study will involve routine checks and tests that are typically done for CPPD, along with some advanced testing not usually performed in regular care.

To be eligible for the trial, participants must be at least 65 years old and have a diagnosis of chronic CPPD that meets specific medical criteria. They should also have experienced ongoing joint problems for at least three months. For those with acute CPPD, they will be included if they are part of a previous study and it's their first episode. Participants will need to give their consent to join the study, and there are some specific health conditions that would exclude someone from participating. This trial aims to provide new insights into CPPD and help improve treatment options for those affected by this condition.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria - Acute forms of CPPD: retrospective part of the study
• • Cases included in the COLCHICORT cohort (NCT03128905), for whom this was the first acute episode of CPPD
• • Inclusion Criteria - Chronical forms of CPPD : prospective part of the study
• • Patients affiliated to the French social security system
• • Age ≥ 65 years
• • Diagnosis of chronic CPPD (recurrent acute or persistent arthritis), meeting ACR/EULAR 2023,11 classification criteria after evaluation by a rheumatologist in the rheumatology department
• • Progression of CPPD rheumatism for at least 3 months and still active CPPD rheumatism, defined by a visual analogue scale (VAS) of disease activity ≥ 40 and/or presentation of at least 1 crisis over the last 3 months
• • Glomerular Filtration Rate (GFR) in Chronic Kidney Disease Epidemiology (CKD EPI Collaboration) ≥ 30ml/min/1.73m2
• • Minimum time between the last intake of a crisis treatment and inclusion in the study, depending on their half-life, in order to not interfere with the results of the omics analyses: 2 weeks (Nonsteroidal Anti-Inflammatory Drugs Per Os (PO) or Intramuscular (IM) or Intravenous (IV); corticosteroids PO or IV; colchicine PO; anakinra Subcutaneous (SC), 1 month (methotrexate PO, tocilizumab SC), 3 months (canakinumab SC, tocilizumab IV)
• • Signed written consent for study participation
• Exclusion Criteria - Acute forms of CPPD:
• • Missing data concerning transcriptomic and metabolomic analyses.
• • Opposition
• Exclusion Criteria - For chronic forms of CPPD:
• • History of gout or presence of monosodium urate (MSU) crystals on joint fluid,
• • Cognitive decline (confusion and neurodegenerative diseases)
• • Inability to provide informed consent and disease VAS
• • Patient under guardianship or curatorship